Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ANRO is expected to report earnings to rise 26.92% to -66 cents per share on March 20
Q4'25
Est.
$-0.66
Q3'25
Beat
by $0.12
Q2'25
Missed
by $0.05
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.03
The last earnings report on November 12 showed earnings per share of -51 cents, beating the estimate of -63 cents. With 121.00K shares outstanding, the current market capitalization sits at 617.60M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ANRO showed earnings on November 12, 2025. You can read more about the earnings report here.